Institution
University of Belgrade
Education•Belgrade, Serbia•
About: University of Belgrade is a education organization based out in Belgrade, Serbia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 20667 authors who have published 47148 publications receiving 896243 citations. The organization is also known as: Univerzitet u Beogradu & Belgrade University.
Topics: Population, Large Hadron Collider, Adsorption, Lepton, Higgs boson
Papers published on a yearly basis
Papers
More filters
••
University of Belgrade1, British Heart Foundation2, National and Kapodistrian University of Athens3, Charité4, St George's, University of London5, VU University Medical Center6, Pierre-and-Marie-Curie University7, Karolinska University Hospital8, University of Groningen9, Cyprus University of Technology10, Academy for Urban School Leadership11, Aarhus University Hospital12, Paris Diderot University13, Keele University14, Utrecht University15, University of Glasgow16, University of Cambridge17, National Institutes of Health18, University Medical Center Groningen19, University of Zurich20
TL;DR: The coexistence of type 2 diabetes mellitus and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent and associated with a higher risk of HF hospitalization, all‐cause and cardiovascular (CV) mortality.
Abstract: The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both disorders in the clinical practice. There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population have shown that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and insulin have been the traditional second- and third-line therapies although their safety in HF is equivocal. Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization. Indeed, a DPP4 inhibitor, saxagliptin, has been associated with a higher risk of HF hospitalization. Thiazolidinediones (pioglitazone and rosiglitazone) are contraindicated in patients with (or at risk of) HF. In recent trials, sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have both shown a significant reduction in HF hospitalization in patients with established CV disease or at risk of CV disease. Several ongoing trials should provide an insight into the effectiveness of SGLT2 inhibitors in patients with HFrEF and HFpEF in the absence of T2DM.
389 citations
••
18 Jan 2013
TL;DR: In this article, the authors measured the centrality of inelastic Pb-Pb collisions at a center-of-mass energy of 2.76 TeV per colliding nucleon pair with ALICE.
Abstract: This publication describes the methods used to measure the centrality of inelastic Pb-Pb collisions at a center-of-mass energy of 2.76 TeV per colliding nucleon pair with ALICE. The centrality is a key parameter in the study of the properties of QCD matter at extreme temperature and energy density, because it is directly related to the initial overlap region of the colliding nuclei. Geometrical properties of the collision, such as the number of participating nucleons and the number of binary nucleon-nucleon collisions, are deduced from a Glauber model with a sharp impact parameter selection and shown to be consistent with those extracted from the data. The centrality determination provides a tool to compare ALICE measurements with those of other experiments and with theoretical calculations.
388 citations
••
TL;DR: The use of radial‐artery grafts for CABG resulted in a lower rate of adverse cardiac events and a higher rate of patency at 5 years of follow‐up, compared with the use of saphenous‐vein grafts.
Abstract: Background The use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result in better postoperative outcomes than the use of saphenous-vein grafts. However, randomized, controlled trials comparing radial-artery grafts and saphenous-vein grafts have been individually underpowered to detect differences in clinical outcomes. We performed a patient-level combined analysis of randomized, controlled trials to compare radial-artery grafts and saphenous-vein grafts for CABG. Methods Six trials were identified. The primary outcome was a composite of death, myocardial infarction, or repeat revascularization. The secondary outcome was graft patency on follow-up angiography. Mixed-effects Cox regression models were used to estimate the treatment effect on the outcomes. Results A total of 1036 patients were included in the analysis (534 patients with radial-artery grafts and 502 patients with saphenous-vein grafts). After a mean (±SD) follow-up time of 60±30 months, the incidence of adver...
387 citations
••
TL;DR: Short and long term studies conducted on Pb or Cd-induced oxidative stress in blood, liver and kidneys as the most prominent target organs of the toxicity of these metals are reviewed and the possible molecular mechanisms of the observed effects are proposed.
381 citations
••
University Hospital of Basel1, University Medical Center Groningen2, University of California, San Diego3, University of Glasgow4, University of Warwick5, Monash University6, University of Brescia7, University of Paris8, University of Zurich9, University of Ljubljana10, University of Cyprus11, National and Kapodistrian University of Athens12, University of Belgrade13, Autonomous University of Barcelona14, University of Otago15, National University of Singapore16, Harvard University17
TL;DR: Screening with NPs for the early detection of relevant cardiac disease including left ventricular systolic dysfunction in patients with cardiovascular risk factors may help to identify patients at increased risk, therefore allowing targeted preventive measures to prevent HF.
Abstract: Natriuretic peptide [NP; B-type NP (BNP), N-terminal proBNP (NT-proBNP), and midregional proANP (MR-proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, intracardiac filling pressures, and intracardiac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracardiac volumes and filling pressures. NPs should be measured in all patients presenting with symptoms suggestive of HF such as dyspnoea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnoea: the higher the NP, the higher the likelihood that dyspnoea is caused by HF. Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in patients presenting to the emergency department with acute dyspnoea are higher compared with those used in the diagnosis of chronic HF in patients with dyspnoea on exertion (mild increase in filling pressures at rest). Obese patients have lower NP concentrations, mandating the use of lower cut-off concentrations (about 50% lower). In stable HF patients, but also in patients with other cardiac disorders such as myocardial infarction, valvular heart disease, atrial fibrillation or pulmonary embolism, NP concentrations have high prognostic accuracy for death and HF hospitalization. Screening with NPs for the early detection of relevant cardiac disease including left ventricular systolic dysfunction in patients with cardiovascular risk factors may help to identify patients at increased risk, therefore allowing targeted preventive measures to prevent HF. BNP, NT-proBNP and MR-proANP have comparable diagnostic and prognostic accuracy. In patients with shock, NPs cannot be used to identify cause (e.g. cardiogenic vs. septic shock), but remain prognostic. NPs cannot identify the underlying cause of HF and, therefore, if elevated, must always be used in conjunction with cardiac imaging.
379 citations
Authors
Showing all 21031 results
Name | H-index | Papers | Citations |
---|---|---|---|
John J.V. McMurray | 178 | 1389 | 184502 |
Barry Halliwell | 173 | 662 | 159518 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Guenakh Mitselmakher | 165 | 1951 | 164435 |
H. Eugene Stanley | 154 | 1190 | 122321 |
Jovan Milosevic | 152 | 1433 | 106802 |
Nikolay Tyurin | 142 | 1270 | 101170 |
Andrew J. Lees | 140 | 877 | 91605 |
Y. B. Hsiung | 138 | 1258 | 94278 |
Lihong V. Wang | 136 | 1118 | 72482 |
Maria Spiropulu | 135 | 1455 | 96674 |
C. Haber | 135 | 1507 | 98014 |
Gabor Istvan Veres | 135 | 1349 | 96104 |
Francisco Matorras | 134 | 1428 | 94627 |
Aldo P. Maggioni | 134 | 940 | 90242 |